FIG 6.

Validation of SARS-CoV-2 pseudovirus and ACE2 expression in different cells. (A) Western blot analysis to validate the incorporation of the S spike protein in the SARS-CoV-2 pseudovirus using the SARS spike protein antibody (Novus Biologicals), which targets the spike protein S2. (B) Infection of cells expressing different levels of ACE2, with the same amounts of SARS-CoV-2 pseudovirus. Columns represent the means ± standard deviations (n = 3). (C) Immunoblot analysis of cell lysates to evaluate ACE2 expression. β-Actin was used as a loading control.